FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1848836475> ?p ?o ?g. }

• W1848836475 endingPage "1544" @default.
• W1848836475 startingPage "1538" @default.
• W1848836475 abstract "We report on a phase II clinical trial to determine the effect of a concurrent ultra-fractionated radiotherapy and temozolomide treatment in inoperable glioblastoma patients. A phase II study opened; patients over 18 years of age who were able to give informed consent and had histologically proven, newly diagnosed inoperable diagnosed and supratentorial glioblastoma were eligible. Three doses of 0.75 Gy spaced apart by at least 4 hr were delivered daily, 5 days a week for six consecutive weeks for a total of 67.5 Gy. Chemotherapy was administered during the same period, which consisted of temozolomide given at a dose of 75 mg/m(2) for 7 days a week. After a 4-week break, chemotherapy was resumed for up to six cycles of adjuvant temozolomide treatment, given every 28 days, according to the standard 5-day regimen. Tolerance and toxicity were the primary endpoints; survival and progression-free survival were the secondary endpoints. In total, 40 patients were enrolled in this study, 29 men and 11 women. The median age was 58 years, and the median Karnofsky performance status was 80. The concomitant ultra-fractionated radiotherapy and temozolomide treatment was well tolerated. Complete responses were seen in four patients, and partial responses were reported in seven patients. The median survival from the initial diagnosis was 16 months. Several long-term survivors were noted. Concurrent ultra-fractionated radiation therapy and temozolomide treatment are well accepted by the patients. The results showed encouraging survival rates for these unfavorable patients." @default.
• W1848836475 created "2016-06-24" @default.
• W1848836475 creator A5038129366 @default.
• W1848836475 creator A5040941950 @default.
• W1848836475 creator A5050615188 @default.
• W1848836475 creator A5063276003 @default.
• W1848836475 creator A5076729444 @default.
• W1848836475 creator A5088445036 @default.
• W1848836475 creator A5089136851 @default.
• W1848836475 creator A5090901098 @default.
• W1848836475 creator A5091353600 @default.
• W1848836475 date "2015-11-20" @default.
• W1848836475 modified "2023-10-13" @default.
• W1848836475 title "A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma" @default.
• W1848836475 cites W1959628099 @default.
• W1848836475 cites W1966965061 @default.
• W1848836475 cites W1975664090 @default.
• W1848836475 cites W1981856835 @default.
• W1848836475 cites W2002299317 @default.
• W1848836475 cites W2003438982 @default.
• W1848836475 cites W2022184716 @default.
• W1848836475 cites W2036224751 @default.
• W1848836475 cites W2039611104 @default.
• W1848836475 cites W2064229709 @default.
• W1848836475 cites W2072153851 @default.
• W1848836475 cites W2072427334 @default.
• W1848836475 cites W2088925558 @default.
• W1848836475 cites W2092033495 @default.
• W1848836475 cites W2095469626 @default.
• W1848836475 cites W2096287682 @default.
• W1848836475 cites W2096609221 @default.
• W1848836475 cites W2097420808 @default.
• W1848836475 cites W2109930640 @default.
• W1848836475 cites W2116575184 @default.
• W1848836475 cites W2120805724 @default.
• W1848836475 cites W2124736921 @default.
• W1848836475 cites W2138334516 @default.
• W1848836475 cites W2139008103 @default.
• W1848836475 cites W2152414287 @default.
• W1848836475 cites W2156330848 @default.
• W1848836475 cites W2158681922 @default.
• W1848836475 cites W314953451 @default.
• W1848836475 cites W4244344354 @default.
• W1848836475 cites W4255289481 @default.
• W1848836475 doi "https://doi.org/10.1002/ijc.29898" @default.
• W1848836475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26501997" @default.
• W1848836475 hasPublicationYear "2015" @default.
• W1848836475 type Work @default.
• W1848836475 sameAs 1848836475 @default.
• W1848836475 citedByCount "6" @default.
• W1848836475 countsByYear W18488364752016 @default.
• W1848836475 countsByYear W18488364752019 @default.
• W1848836475 countsByYear W18488364752020 @default.
• W1848836475 countsByYear W18488364752021 @default.
• W1848836475 countsByYear W18488364752022 @default.
• W1848836475 crossrefType "journal-article" @default.
• W1848836475 hasAuthorship W1848836475A5038129366 @default.
• W1848836475 hasAuthorship W1848836475A5040941950 @default.
• W1848836475 hasAuthorship W1848836475A5050615188 @default.
• W1848836475 hasAuthorship W1848836475A5063276003 @default.
• W1848836475 hasAuthorship W1848836475A5076729444 @default.
• W1848836475 hasAuthorship W1848836475A5088445036 @default.
• W1848836475 hasAuthorship W1848836475A5089136851 @default.
• W1848836475 hasAuthorship W1848836475A5090901098 @default.
• W1848836475 hasAuthorship W1848836475A5091353600 @default.
• W1848836475 hasBestOaLocation W18488364751 @default.
• W1848836475 hasConcept C126322002 @default.
• W1848836475 hasConcept C141071460 @default.
• W1848836475 hasConcept C203092338 @default.
• W1848836475 hasConcept C2776194525 @default.
• W1848836475 hasConcept C2776694085 @default.
• W1848836475 hasConcept C2777389519 @default.
• W1848836475 hasConcept C2779384505 @default.
• W1848836475 hasConcept C2780739268 @default.
• W1848836475 hasConcept C2781413609 @default.
• W1848836475 hasConcept C31760486 @default.
• W1848836475 hasConcept C502942594 @default.
• W1848836475 hasConcept C509974204 @default.
• W1848836475 hasConcept C535046627 @default.
• W1848836475 hasConcept C71924100 @default.
• W1848836475 hasConceptScore W1848836475C126322002 @default.
• W1848836475 hasConceptScore W1848836475C141071460 @default.
• W1848836475 hasConceptScore W1848836475C203092338 @default.
• W1848836475 hasConceptScore W1848836475C2776194525 @default.
• W1848836475 hasConceptScore W1848836475C2776694085 @default.
• W1848836475 hasConceptScore W1848836475C2777389519 @default.
• W1848836475 hasConceptScore W1848836475C2779384505 @default.
• W1848836475 hasConceptScore W1848836475C2780739268 @default.
• W1848836475 hasConceptScore W1848836475C2781413609 @default.
• W1848836475 hasConceptScore W1848836475C31760486 @default.
• W1848836475 hasConceptScore W1848836475C502942594 @default.
• W1848836475 hasConceptScore W1848836475C509974204 @default.
• W1848836475 hasConceptScore W1848836475C535046627 @default.
• W1848836475 hasConceptScore W1848836475C71924100 @default.
• W1848836475 hasIssue "6" @default.
• W1848836475 hasLocation W18488364751 @default.
• W1848836475 hasLocation W18488364752 @default.
• W1848836475 hasLocation W18488364753 @default.

• next